Prestige Consumer Healthcare (PBH) Competitors

Prestige Consumer Healthcare (NYSE:PBH) and Interparfums (NASDAQ:IPAR) are both mid-cap personal products companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

Which has preferable earnings & valuation, PBH or IPAR?

Prestige Consumer Healthcare has higher earnings, but lower revenue than Interparfums. Prestige Consumer Healthcare is trading at a lower price-to-earnings ratio than Interparfums, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prestige Consumer Healthcare	$1.14B	3.47	$214.60M	$4.29	18.64
Interparfums	$1.45B	3.06	$164.36M	$5.14	26.95

Do institutionals & insiders hold more shares of PBH or IPAR?

100.0% of Prestige Consumer Healthcare shares are held by institutional investors. Comparatively, 55.6% of Interparfums shares are held by institutional investors. 1.6% of Prestige Consumer Healthcare shares are held by insiders. Comparatively, 43.9% of Interparfums shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Does the media refer more to PBH or IPAR?

In the previous week, Interparfums had 1 more articles in the media than Prestige Consumer Healthcare. MarketBeat recorded 5 mentions for Interparfums and 4 mentions for Prestige Consumer Healthcare. Prestige Consumer Healthcare's average media sentiment score of 1.26 beat Interparfums' score of 1.18 indicating that Prestige Consumer Healthcare is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prestige Consumer Healthcare	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Interparfums	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk and volatility, PBH or IPAR?

Prestige Consumer Healthcare has a beta of 0.43, suggesting that its stock price is 57% less volatile than the S&P 500. Comparatively, Interparfums has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500.

Is PBH or IPAR more profitable?

Prestige Consumer Healthcare has a net margin of 18.86% compared to Interparfums' net margin of 11.30%. Interparfums' return on equity of 17.62% beat Prestige Consumer Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prestige Consumer Healthcare	18.86%	12.87%	6.78%
Interparfums	11.30%	17.62%	11.86%

Do analysts prefer PBH or IPAR?

Prestige Consumer Healthcare currently has a consensus target price of $93.33, indicating a potential upside of 16.70%. Interparfums has a consensus target price of $157.60, indicating a potential upside of 13.78%. Given Prestige Consumer Healthcare's higher probable upside, analysts plainly believe Prestige Consumer Healthcare is more favorable than Interparfums.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prestige Consumer Healthcare	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Interparfums	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Interparfums beats Prestige Consumer Healthcare on 10 of the 16 factors compared between the two stocks.